TY  - JOUR
AU  - Sopić, Miron
AU  - Vladimirov, Sandra
AU  - Munjas, Jelena
AU  - Mitić, Tijana
AU  - Hall, Ignacio Fernando
AU  - Jušić, Amela
AU  - Ružić, Dušan
AU  - Devaux, Yvan
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5637
AB  - Noncoding RNAs (ncRNAs) are pivotal for various pathological processes, impacting disease progression. The potential for leveraging ncRNAs to prevent or treat atherosclerosis and associated cardiovascular diseases is of great significance, especially given the increasing prevalence of atherosclerosis in an ageing and sedentary population. Together, these diseases impose a substantial socio-economic burden, demanding innovative therapeutic solutions. This review explores the potential of ncRNAs in atherosclerosis treatment. We commence by examining approaches for identifying and characterizing atherosclerosis-associated ncRNAs. We then delve into the functional aspects of ncRNAs in atherosclerosis development and progression. Additionally, we review current RNA and RNA-targeting molecules in development or under approval for clinical use, offering insights into their pharmacological potential. The importance of improved ncRNA delivery strategies is highlighted. Finally, we suggest avenues for advanced research to accelerate the use of ncRNAs in treating atherosclerosis and mitigating its societal impact.
PB  - John Wiley and Sons Inc
T2  - British Journal of Pharmacology
T1  - Targeting noncoding RNAs to treat atherosclerosis
DO  - 10.1111/bph.16412
ER  - 

@article{
author = "Sopić, Miron and Vladimirov, Sandra and Munjas, Jelena and Mitić, Tijana and Hall, Ignacio Fernando and Jušić, Amela and Ružić, Dušan and Devaux, Yvan",
year = "2024",
abstract = "Noncoding RNAs (ncRNAs) are pivotal for various pathological processes, impacting disease progression. The potential for leveraging ncRNAs to prevent or treat atherosclerosis and associated cardiovascular diseases is of great significance, especially given the increasing prevalence of atherosclerosis in an ageing and sedentary population. Together, these diseases impose a substantial socio-economic burden, demanding innovative therapeutic solutions. This review explores the potential of ncRNAs in atherosclerosis treatment. We commence by examining approaches for identifying and characterizing atherosclerosis-associated ncRNAs. We then delve into the functional aspects of ncRNAs in atherosclerosis development and progression. Additionally, we review current RNA and RNA-targeting molecules in development or under approval for clinical use, offering insights into their pharmacological potential. The importance of improved ncRNA delivery strategies is highlighted. Finally, we suggest avenues for advanced research to accelerate the use of ncRNAs in treating atherosclerosis and mitigating its societal impact.",
publisher = "John Wiley and Sons Inc",
journal = "British Journal of Pharmacology",
title = "Targeting noncoding RNAs to treat atherosclerosis",
doi = "10.1111/bph.16412"
}

Sopić, M., Vladimirov, S., Munjas, J., Mitić, T., Hall, I. F., Jušić, A., Ružić, D.,& Devaux, Y.. (2024). Targeting noncoding RNAs to treat atherosclerosis. in British Journal of Pharmacology
John Wiley and Sons Inc..
https://doi.org/10.1111/bph.16412

Sopić M, Vladimirov S, Munjas J, Mitić T, Hall IF, Jušić A, Ružić D, Devaux Y. Targeting noncoding RNAs to treat atherosclerosis. in British Journal of Pharmacology. 2024;.
doi:10.1111/bph.16412 .

Sopić, Miron, Vladimirov, Sandra, Munjas, Jelena, Mitić, Tijana, Hall, Ignacio Fernando, Jušić, Amela, Ružić, Dušan, Devaux, Yvan, "Targeting noncoding RNAs to treat atherosclerosis" in British Journal of Pharmacology (2024),
https://doi.org/10.1111/bph.16412 . .

TY  - JOUR
AU  - Petković, Aleksa
AU  - Erceg, Sanja
AU  - Munjas, Jelena
AU  - Ninić, Ana
AU  - Vladimirov, Sandra
AU  - Davidović, Aleksandar
AU  - Vukmirović, Luka
AU  - Milanov, Marko
AU  - Cvijanović, Dane
AU  - Mitić, Tijana
AU  - Sopić, Miron
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4955
AB  - Current clinical data show that, despite constant efforts to develop novel therapies and clinical approaches, atherosclerotic cardiovascular diseases (ASCVD) are still one of the leading causes of death worldwide. Advanced and unstable atherosclerotic plaques most often trigger acute coronary events that can lead to fatal outcomes. However, despite the fact that different plaque phenotypes may require different treatments, current approaches to prognosis, diagnosis, and classification of acute coronary syndrome do not consider the diversity of plaque phenotypes. Long non-coding RNAs (lncRNAs) represent an important class of molecules that are implicated in epigenetic control of numerous cellular processes. Here we review the latest knowledge about lncRNAs’ influence on plaque development and stability through regulation of immune response, lipid metabolism, extracellular matrix remodelling, endothelial cell function, and vascular smooth muscle function, with special emphasis on pro-atherogenic and anti-atherogenic lncRNA functions. In addition, we present current challenges in the research of lncRNAs’ role in atherosclerosis and translation of the findings from animal models to humans. Finally, we present the directions for future lncRNA-oriented research, which may ultimately result in patient-oriented therapeutic strategies for ASCVD.
PB  - MDPI
T2  - Cells
T1  - LncRNAs as Regulators of Atherosclerotic Plaque Stability
VL  - 12
IS  - 14
DO  - 10.3390/cells12141832
ER  - 

@article{
author = "Petković, Aleksa and Erceg, Sanja and Munjas, Jelena and Ninić, Ana and Vladimirov, Sandra and Davidović, Aleksandar and Vukmirović, Luka and Milanov, Marko and Cvijanović, Dane and Mitić, Tijana and Sopić, Miron",
year = "2023",
abstract = "Current clinical data show that, despite constant efforts to develop novel therapies and clinical approaches, atherosclerotic cardiovascular diseases (ASCVD) are still one of the leading causes of death worldwide. Advanced and unstable atherosclerotic plaques most often trigger acute coronary events that can lead to fatal outcomes. However, despite the fact that different plaque phenotypes may require different treatments, current approaches to prognosis, diagnosis, and classification of acute coronary syndrome do not consider the diversity of plaque phenotypes. Long non-coding RNAs (lncRNAs) represent an important class of molecules that are implicated in epigenetic control of numerous cellular processes. Here we review the latest knowledge about lncRNAs’ influence on plaque development and stability through regulation of immune response, lipid metabolism, extracellular matrix remodelling, endothelial cell function, and vascular smooth muscle function, with special emphasis on pro-atherogenic and anti-atherogenic lncRNA functions. In addition, we present current challenges in the research of lncRNAs’ role in atherosclerosis and translation of the findings from animal models to humans. Finally, we present the directions for future lncRNA-oriented research, which may ultimately result in patient-oriented therapeutic strategies for ASCVD.",
publisher = "MDPI",
journal = "Cells",
title = "LncRNAs as Regulators of Atherosclerotic Plaque Stability",
volume = "12",
number = "14",
doi = "10.3390/cells12141832"
}

Petković, A., Erceg, S., Munjas, J., Ninić, A., Vladimirov, S., Davidović, A., Vukmirović, L., Milanov, M., Cvijanović, D., Mitić, T.,& Sopić, M.. (2023). LncRNAs as Regulators of Atherosclerotic Plaque Stability. in Cells
MDPI., 12(14).
https://doi.org/10.3390/cells12141832

Petković A, Erceg S, Munjas J, Ninić A, Vladimirov S, Davidović A, Vukmirović L, Milanov M, Cvijanović D, Mitić T, Sopić M. LncRNAs as Regulators of Atherosclerotic Plaque Stability. in Cells. 2023;12(14).
doi:10.3390/cells12141832 .

Petković, Aleksa, Erceg, Sanja, Munjas, Jelena, Ninić, Ana, Vladimirov, Sandra, Davidović, Aleksandar, Vukmirović, Luka, Milanov, Marko, Cvijanović, Dane, Mitić, Tijana, Sopić, Miron, "LncRNAs as Regulators of Atherosclerotic Plaque Stability" in Cells, 12, no. 14 (2023),
https://doi.org/10.3390/cells12141832 . .

TY  - JOUR
AU  - Garratt, Hester
AU  - Ashburn, Robert
AU  - Sopić, Miron
AU  - Nogara, Antonella
AU  - Caporali, Andrea
AU  - Mitić, Tijana
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3978
AB  - The vascular endothelium comprises the interface between the circulation and the vessel wall and, as such, is under the dynamic regulation of vascular signalling, nutrients, and hypoxia. Understanding the molecular drivers behind endothelial cell (EC) and vascular smooth muscle cell (VSMC) function and dysfunction remains a pivotal task for further clinical progress in tackling vascular disease. A newly emerging era in vascular biology with landmark deep sequencing approaches has provided us with the means to profile diverse layers of transcriptional regulation at a single cell, chromatin, and epigenetic level. This review describes the roles of major vascular long non-coding RNA (lncRNAs) in the epigenetic regulation of EC and VSMC function and discusses the recent progress in their discovery, detection, and functional characterisation. We summarise new findings regarding lncRNA-mediated epigenetic mechanisms—often regulated by hypoxia—within the vascular endothelium and smooth muscle to control vascular homeostasis in health and disease. Furthermore, we outline novel molecular techniques being used in the field to delineate the lncRNA subcellular localisation and interaction with proteins to unravel their biological roles in the epigenetic regulation of vascular genes.
PB  - MDPI
T2  - Non-coding RNA
T1  - Long non‐coding RNA regulation of epigenetics in vascular cells
VL  - 7
IS  - 4
DO  - 10.3390/ncrna7040062
ER  - 

@article{
author = "Garratt, Hester and Ashburn, Robert and Sopić, Miron and Nogara, Antonella and Caporali, Andrea and Mitić, Tijana",
year = "2021",
abstract = "The vascular endothelium comprises the interface between the circulation and the vessel wall and, as such, is under the dynamic regulation of vascular signalling, nutrients, and hypoxia. Understanding the molecular drivers behind endothelial cell (EC) and vascular smooth muscle cell (VSMC) function and dysfunction remains a pivotal task for further clinical progress in tackling vascular disease. A newly emerging era in vascular biology with landmark deep sequencing approaches has provided us with the means to profile diverse layers of transcriptional regulation at a single cell, chromatin, and epigenetic level. This review describes the roles of major vascular long non-coding RNA (lncRNAs) in the epigenetic regulation of EC and VSMC function and discusses the recent progress in their discovery, detection, and functional characterisation. We summarise new findings regarding lncRNA-mediated epigenetic mechanisms—often regulated by hypoxia—within the vascular endothelium and smooth muscle to control vascular homeostasis in health and disease. Furthermore, we outline novel molecular techniques being used in the field to delineate the lncRNA subcellular localisation and interaction with proteins to unravel their biological roles in the epigenetic regulation of vascular genes.",
publisher = "MDPI",
journal = "Non-coding RNA",
title = "Long non‐coding RNA regulation of epigenetics in vascular cells",
volume = "7",
number = "4",
doi = "10.3390/ncrna7040062"
}

Garratt, H., Ashburn, R., Sopić, M., Nogara, A., Caporali, A.,& Mitić, T.. (2021). Long non‐coding RNA regulation of epigenetics in vascular cells. in Non-coding RNA
MDPI., 7(4).
https://doi.org/10.3390/ncrna7040062

Garratt H, Ashburn R, Sopić M, Nogara A, Caporali A, Mitić T. Long non‐coding RNA regulation of epigenetics in vascular cells. in Non-coding RNA. 2021;7(4).
doi:10.3390/ncrna7040062 .

Garratt, Hester, Ashburn, Robert, Sopić, Miron, Nogara, Antonella, Caporali, Andrea, Mitić, Tijana, "Long non‐coding RNA regulation of epigenetics in vascular cells" in Non-coding RNA, 7, no. 4 (2021),
https://doi.org/10.3390/ncrna7040062 . .